Drugs / VLX600
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02222363 | Feb 2015 → Dec 2016 | refractory malignant neoplasm | Vivolux AB | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VLX600 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02222363 ↗ |
| Known as | Dndi1417324 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4788406 ↗ |
| Modality | Small molecule | — CHEMBL4788406 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT02222363 ↗ |